Moderna signs up Lonza to boost scale-up of mRNA vaccine for coronavirus
Collaboration leverages CDMO’s expertise in tech transfer and manufacturing to aim for 1 million doses per day
Moderna has signed up CDMO Lonza to support larger scale manufacturing of its mRNA vaccine, mRNA-1273, against COVID-19 in a ten-year strategic agreement, the two companies announced on Friday.
Stéphane Bancel, chief executive officer at Moderna said the long-term collaboration would allow the firm to accelerate its manufacturing capacity for mRNA-1273 tenfold.
“Lonza’s global presence and expertise are critical as we scale at unprecedented speed. Our common goal is to potentially enable manufacturing of up to 1 billion doses of mRNA-1273,” he said.
Albert Baehny, chairman and interim CEO at Lonza said the current pandemic illustrated the need to combine the best science with resilient supply chains that can scale.
“We are fully committed to leveraging our global network and experience in manufacturing technologies to support Moderna’s manufacture of mRNA-1273 as well as collaborating on future Moderna products,” he added.
Under the terms of the agreement, manufacturing suites will be established at Lonza’s facilities in the US and Switzerland. Technology transfer is expected to begin in June 2020, and the companies intend to manufacture the first batches of mRNA-1273 at Lonza US in July 2020.
The two partners said that over time, they intend to establish additional production suites across Lonza’s global facilities to be able to produce up to 1 billion doses of mRNA-1273 per year for worldwide use worldwide assuming the currently expected dose of 50 µg.
Last month, Moderna was awarded a grant of up to USD483 million from US government agency Biomedical Advanced Research and Development Authority (BARDA) to accelerate development of mRNA-1273.
The money will also be used to fund manufacturing process scale-up to enable large-scale production in 2020 for pandemic response and Moderna plans to hire 150 new team members to support these efforts.
Last week, Moderna said it had submitted an Investigational New Drug (IND) application to the US Food and Drug Administration for Phase 2 – expected to start this quarter - and late stage studies of mRNA-1273 if supported by safety data from a Phase 1 study.
Related News
-
News Pharmapack Awards 2024 Patient-Centric Design Award Winner – Dr Ferrer BioPharma
The 2024 Pharmapack Awards celebrated the best in innovation and design for the pharmaceutical packaging and drug delivery industry on January 24, 2024. -
News Women in Pharma: Minding the Gap at Pharmapack 2024
2024 marks the first year Pharmapack will host a Diversity track dedicated to bridging the gap within the pharmaceutical packaging and drug delivery sector. The track includes a panel discussion on 'Enabling Diversity in the Workplace,' focused... -
News Pharmapack Awards 2024 - Celebrating Packaging and Drug Delivery Innovation
The 2024 Pharmapack Innovation Awards ceremony celebrated the best in pharmaceutical packaging and drug delivery innovation at all levels. The awards were held on January 24, 2024 at the Paris Expo Porte de Versailles. -
News 2024 Pharma Industry Trends Outlook: Collaboration, Market Maturity, and Digital Futures
The annual CPHI Online 2024 Pharma Trends Outlook, in partnership with Arvato Systems, identifies 12 key industry trends shaping the life sciences industry in the coming year. -
News New Novo Nordisk AI hub for drug discovery to open in London, UK
Danish pharmaceutical giant Novo Nordisk will be opening an AI-based research facility in the heart of London to advance drug discovery operations. -
News BioNTech to begin mRNA vaccine manufacturing in Rwanda by 2025
German biotechnology company BioNTech has stated their intentions to begin production at their mRNA vaccine factory in Rwanda by 2025, which will mark the first foreign mRNA vaccine manufacturing site on the continent of Africa. -
News Women in Pharma: Looking back on 2023 and moving forward to 2024
In this monthly series, we interview women from across the pharmaceutical industry and supply chain to discuss the importance of gender diversity in healthcare, the workplace, and beyond. -
News CPHI Barcelona 2023: Partnering for Success – Managing Outsourcing Relationships to Optimise Manufacturing Operations
During CPHI Barcelona 2023, insightful content sessions offered attendees the chance to explore trending topics with expert speakers and panellists. Here, we summarise what the pharma industry and supply chain are talking about the most.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance